Caribou Halts Lead CAR-T Programs, Explores Strategic Alternatives
CRBU is trading near its 52-week low of $1.13 (0.4% above the low).
Summary
Caribou Biosciences is discontinuing its two lead allogeneic CAR-T programs and cutting most of its workforce while exploring strategic alternatives. This follows the Q2 2026 results in August that showed a $24.3M net loss and a 12-month cash runway. The halt removes the company's core clinical assets, leaving the pipeline without near-term value drivers. With the stock trading near its 52-week low of $1.13, the move signals a fundamental shift away from its CAR-T platform. The 8-K filed today confirms the workforce reduction and strategic review, indicating the company is now focused on preserving cash and evaluating options.
At the time of this announcement, CRBU was trading at $1.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $121.7M. The 52-week trading range was $1.13 to $3.54. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Seeking Alpha.